+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Keppra"

CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • April 2025
  • 898 Pages
  • Global
From
From
From
Research Report on China's Levetiracetam Market, 2021-2025 - Product Thumbnail Image

Research Report on China's Levetiracetam Market, 2021-2025

  • Report
  • September 2021
  • 40 Pages
  • China
From
From
Keppra - API Insight, 2022 - Product Thumbnail Image

Keppra - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Keppra is a brand name of the antiepileptic drug levetiracetam, which is used to treat epilepsy and other seizure disorders. It is a member of the Central Nervous System (CNS) drug class, which includes drugs used to treat neurological conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Keppra is approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial onset seizures in adults and children aged four years and older. It is also approved for the treatment of myoclonic seizures in adults and children aged 12 years and older. Keppra is available in both oral and intravenous formulations. It is marketed by UCB, Inc., a biopharmaceutical company based in Belgium. Other companies that market levetiracetam include Mylan Pharmaceuticals, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more